RESTENOSIS AFTER CORONARY ANGIOPLASTY
RESTENOSIS AFTER CORONARY ANGIOPLASTY
复制标题
DOI：
10.1093/eurheartj/16.suppl_i.33
复制
发表时间：
1995-08-01
影响因子：
39.3
通讯作者：
BERTRAND, ME
中科院分区：
文献类型：
--
作者：
HAMON, M;BAUTERS, C;BERTRAND, ME
使用经皮冠状动脉腔内成形术治疗动脉粥样硬化性冠状动脉疾病的主要缺点是在最初成功的手术后经常发生再狭窄。对动物的研究和对人体的组织学观察表明，再狭窄的特征是由于平滑肌细胞增殖和细胞外基质的合成而导致的新内膜增生。技术或药物干预的改进对再狭窄率没有显着影响。尽管我们对再狭窄的分子机制有了更多的了解，但目前尚无有效的治疗方法。基因疗法在实验模型中取得了令人鼓舞的初步结果，可能在中期提供解决方案。
The major disadvantage of using percutaneous transluminal coronary angioplasty to treat patients with atherosclerotic coronary disease is the frequent occurrence of restenosis after an initially successful procedure. Studies in animals and histological observations in man have demonstrated that restenosis is characterized by neointimal hyperplasia due to smooth muscle cell proliferation and to the synthesis of extracellular matrix. Improvements in technology or pharmacological interventions have had no significant impact on the rate of restenosis. In spite of our increased understanding of the molecular mechanisms of restenosis, no effective treatment is available at the present time. Gene therapy which has produced encouraging initial results in experimental models, may provide a solution in the medium term.